Chimeric antigen receptor (CAR)-T therapy has been developed as revolutionary treatment in cancer treatment. It has been clinically proven to be effective and durable towards certain subtypes of blood cancer especially in B-cell leukemia or lymphoma. CARs are synthetic receptor which are designed to redirect T lymphocytes to eliminate cancer cells with a specific antigen on the surface. However, limited therapeutic efficacy and safety concern of CAR-T therapy present as obstacles to its application in both solid and hematological cancer. Hence more research is being conducted to study the mechanism behind therapeutic limitation and how to improve its therapeutic effectiveness. Furthermore, innovative strategies should be investigated to limit its toxicities. This review firstly explains the process of CAR-T therapy and its current milestone. Then the review discusses its current challenges and characterize some reasons for its limited therapeutic applications and strategies to improve its efficacy and safety in clinical settings.
No takes yet. Share an insight, caveat, or question.
Xinyi Sheng (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: